LONDON (Alliance News) - Sareum Holdings PLC said Monday it has been granted a patent from the European Patent Officer for inventions related to its Tyrosine kinase inhibitor programme.
The patent covers compounds that inhibit the Janus kinase family of enzymes function, in particular Tyrosine kinase, and the use of these compounds in the treatment of disease mediated by these kinase enzymes including autoimmune diseases like multiple sclerosis, psoriasis and inflammatory bowel disease.
Sareum said that the granting of this patent means it will have improved protection in Europe for the programme. It expects to be granted similar patents in other markets including the US in "due course".
Shares in Sareum are trading up 11% at 0.471 pence Monday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Sareum (SAR)